Brokerages Set PDS Biotechnology Co. (NASDAQ:PDSB) Target Price at $14.25

Shares of PDS Biotechnology Co. (NASDAQ:PDSB) have been assigned an average recommendation of “Buy” from the five analysts that are covering the company, MarketBeat reports. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $14.25.

A number of research firms have recently commented on PDSB. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a research report on Thursday, October 24th.

PDS Biotechnology Stock Performance

Shares of NASDAQ PDSB opened at $3.29 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. The firm has a fifty day moving average price of $3.25 and a 200-day moving average price of $3.28. The stock has a market cap of $121.14 million, a PE ratio of -2.70 and a beta of 1.93. PDS Biotechnology has a 1 year low of $2.53 and a 1 year high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same quarter in the previous year, the company posted ($0.37) earnings per share. Equities analysts anticipate that PDS Biotechnology will post -1.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in PDS Biotechnology by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after acquiring an additional 82,135 shares during the period. Blair William & Co. IL grew its holdings in shares of PDS Biotechnology by 204.4% in the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after purchasing an additional 81,743 shares during the last quarter. Tempus Wealth Planning LLC purchased a new position in PDS Biotechnology in the 2nd quarter worth about $55,000. Cubist Systematic Strategies LLC bought a new stake in PDS Biotechnology during the 2nd quarter valued at about $146,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in PDS Biotechnology in the 2nd quarter valued at about $115,000. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.